Novo Nordisk A/S,
NYSE: NVO, a Denmark based global pharma giant, has been one of my top healthcare picks since long time. Why? Simple reasons:
- Impressive & deep pipeline
- Pipeline primarily focused on Diabetes, a chronic disease which has been delivering global burden to healthcare. According to International Diabetes Federation, approximately 552 million people in world will have diabetes.
- Sustainable equity and cash flow growth
 |
Source: Yahoo Finance
|
At the end of Q2 2013, NVO announced better outlook for the rest of 2013 as compared to their announcement of outlook on May 1. Booming sales of Victoza, Modern Insulins and their other long standing diabetes products have given them a great position in this disease sector. And they will continue to do that as per analysts' expectations.
No comments:
Post a Comment